Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu klinické zkoušky, fáze IV, časopisecké články
PubMed
31084373
DOI
10.2217/fon-2018-0934
Knihovny.cz E-zdroje
- Klíčová slova
- VEGF, biomarkers, efficacy, pancreatic neuroendocrine tumor, sunitinib,
- MeSH
- doba přežití bez progrese choroby MeSH
- farmakogenomické testování MeSH
- inhibitory proteinkinas aplikace a dávkování škodlivé účinky MeSH
- interleukin-1beta genetika MeSH
- jednonukleotidový polymorfismus MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory slinivky břišní farmakoterapie genetika mortalita MeSH
- neuroendokrinní nádory farmakoterapie genetika mortalita MeSH
- senioři MeSH
- sunitinib aplikace a dávkování škodlivé účinky MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze IV MeSH
- Názvy látek
- IL1B protein, human MeSH Prohlížeč
- inhibitory proteinkinas MeSH
- interleukin-1beta MeSH
- sunitinib MeSH
Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.
Boston University and Boston Medical Center Boston MA USA
Centrul de Oncologie Sf Nectarie Oncologie Medicala Craiova Romania
Department of Gastroenterology Oslo University Hospital Rikshospitalet Oslo Norway
Department of Medical Oncology Fundeni Clinical Institute Bucharest Romania
Department of Medical Oncology Paris Saint Joseph Hospital Group Paris France
Faculty of Medicine Masaryk Memorial Cancer Institute Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
